Anti-TNF-A Therapy about Infliximab and Adalimamab for the Effectiveness in Ulcerative Colitis Compared with Conventional Therapy: A Meta-Analysis
- PMID: 26902011
Anti-TNF-A Therapy about Infliximab and Adalimamab for the Effectiveness in Ulcerative Colitis Compared with Conventional Therapy: A Meta-Analysis
Abstract
Background/aims: TNF-α has an important role in the pathogenesis of ulcerative colitis (UC). It seems that anti-TNF-α therapy is beneficial in the treatment of UC. The aim was to assess the effectiveness of Infliximab and Adalimamab with UC compared with con- ventional therapy.
Methodology: The Pubmed and Embase databases were searched for studies investigating the efficacy of infliximab and adalimumab on UC.
Results: Infliximab had a statistically significant effects in induction of clinical response (RR = 1.67; 95% CI 1.12 to 2.50) of UC compared with conventional therapy, but those had not a statistically significant effects in clinical remission (RR = 1.63; 95% CI 0.84 to 3.18) and reduction of colectomy rate (RR = 0.54; 95% CI 0.26 to 1.12) of UC. And adalimumab had a statistically significant effects in induction of clinical remission (RR =1.82; 95% CI 1.24 to 2.67) and clinical response (RR =1.36; 95% CI 1.13 to 1.64) of UC compared with conventional therapy.
Conclusion: Our meta-analyses suggested that Infliximab had a statistically significant effects in induction of clinical response of UC compared with conventional therapy and adalimumab had a statistically significant effects in induction of clinical remission and clinical response of UC compared with conventional therapy.
Similar articles
-
Anti-TNF-A therapy about infliximab and adalimamab for the effectiveness in ulcerative colitis compared with conventional therapy: a meta-analysis.Hepatogastroenterology. 2015 Mar-Apr;62(138):309-18. Hepatogastroenterology. 2015. PMID: 25916055 Review.
-
Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.J Clin Gastroenterol. 2015 Sep;49(8):675-82. doi: 10.1097/MCG.0000000000000265. J Clin Gastroenterol. 2015. PMID: 25389599
-
Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials.Dig Liver Dis. 2015 May;47(5):356-64. doi: 10.1016/j.dld.2015.01.148. Epub 2015 Jan 22. Dig Liver Dis. 2015. PMID: 25661014
-
Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study).Scand J Gastroenterol. 2016;51(2):186-95. doi: 10.3109/00365521.2015.1070900. Epub 2015 Jul 22. Scand J Gastroenterol. 2016. PMID: 26200929
-
Treatment of ulcerative colitis.Curr Opin Gastroenterol. 2014 Jan;30(1):84-96. doi: 10.1097/MOG.0000000000000031. Curr Opin Gastroenterol. 2014. PMID: 24285003 Review.
Cited by
-
Management of Psoriatic Arthritis: Turkish League Against Rheumatism (TLAR) Expert Opinions.Arch Rheumatol. 2018 May 21;33(2):108-127. doi: 10.5606/ArchRheumatol.2018.6946. eCollection 2018 Jun. Arch Rheumatol. 2018. PMID: 30207576 Free PMC article.
-
RIP3 knockdown inhibits necroptosis of human intestinal epithelial cells via TLR4/MyD88/NF-κB signaling and ameliorates murine colitis.BMC Gastroenterol. 2022 Mar 26;22(1):137. doi: 10.1186/s12876-022-02208-x. BMC Gastroenterol. 2022. PMID: 35346043 Free PMC article.
-
Regulatory role of NKG2D+ NK cells in intestinal lamina propria by secreting double-edged Th1 cytokines in ulcerative colitis.Oncotarget. 2017 Oct 30;8(58):98945-98952. doi: 10.18632/oncotarget.22132. eCollection 2017 Nov 17. Oncotarget. 2017. PMID: 29228739 Free PMC article.
-
A prediction of the CRNDE role by modulating NF-κB pathway in inflammatory bowel disease (IBD).Biochem Biophys Rep. 2024 May 11;38:101731. doi: 10.1016/j.bbrep.2024.101731. eCollection 2024 Jul. Biochem Biophys Rep. 2024. PMID: 38766384 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical